HilleVax (NASDAQ:HLVX) Stock Price Down 1.5% Following Weak Earnings

HilleVax, Inc. (NASDAQ:HLVX - Get Free Report)'s stock price fell 1.5% during mid-day trading on Friday following a dissappointing earnings announcement. The company traded as low as $1.85 and last traded at $1.91. 150,420 shares were traded during trading, a decline of 66% from the average session volume of 440,025 shares. The stock had previously closed at $1.94.

The company reported ($0.52) EPS for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.10).

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "neutral" rating and issued a $2.00 target price on shares of HilleVax in a report on Monday, August 12th. Six analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $9.20.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. EntryPoint Capital LLC bought a new position in HilleVax during the 1st quarter worth approximately $80,000. Tidal Investments LLC bought a new position in HilleVax during the 1st quarter worth approximately $207,000. Bank of New York Mellon Corp raised its holdings in HilleVax by 35.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 93,865 shares of the company's stock worth $1,357,000 after purchasing an additional 24,410 shares during the last quarter. Rhumbline Advisers raised its holdings in HilleVax by 27.0% during the 2nd quarter. Rhumbline Advisers now owns 42,658 shares of the company's stock worth $617,000 after purchasing an additional 9,073 shares during the last quarter. Finally, TD Asset Management Inc raised its holdings in HilleVax by 53.9% during the 2nd quarter. TD Asset Management Inc now owns 54,236 shares of the company's stock worth $784,000 after purchasing an additional 19,000 shares during the last quarter. Institutional investors own 86.42% of the company's stock.

HilleVax Stock Performance

The firm's fifty day simple moving average is $1.81 and its 200-day simple moving average is $6.25. The stock has a market cap of $95.08 million, a P/E ratio of -0.56 and a beta of 0.78.

About HilleVax

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.